Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study designed as a multicenter, open label, two-step study to determine the optimum
dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally
advanced or metastatic non-small cell lung cancer (NSCLC). The research is planned as a
two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.
Phase:
Phase 1
Details
Lead Sponsor:
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.